Biggest stock movers Monday: COOP, HSMT, CYRX, PCVX, MRNA, NNOX and more
Stock futures edged lower on Monday due to trade war concerns and the upcoming 25% levy on non-US cars. President Trump has ...
Pulmonology Advisor2h
Atrial Fibrillation Risk Not Increased After RSV Vaccination in High-Risk Older Adults
The risk for new-onset or recurrent AF was not increased among older adult patients with preexisting conditions following RSV vaccination.
European Medical Journal2h
RSV Vaccine Reduces Hospital Admissions by 30% in England
England’s RSV vaccination programme has achieved a 30% reduction in RSV-related hospital admissions among older adults.
Moderna Receives Australian Therapeutic Goods Administration Approval for RSV Vaccine for Older Adults
CAMBRIDGE, MA / ACCESS Newswire / March 31, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Australian Therapeutic Goods Administration (TGA) has granted approval for mRESVIA® (mRNA-1345), ...
Researchers Discover mRNA Vaccines Leave Lasting Mark on the Immune System
Researchers at the University of Cologne have found that mRNA-based COVID-19 vaccines have a lasting impact on the innate ...
PharmiWeb6h
Moderna Receives Medicines and Healthcare Products Regulatory Agency Marketing Authorization in the UK for RSV Vaccine
Moderna, Inc. (NASDAQ:MRNA) today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has granted marketing authorization for mRESVIA (mRNA-1345), indicated for ...
The Manila Times15h
AIM Vaccine reduces losses by nearly 90% in 2024, with the iterative major product series opening up space for explosive growth in performance
AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, published its 2024 Annual Results announcement on March 30, 2025, the company recorded revenues of RMB 1,285 million in 2024, an ...
Immunization program for babies slashes RSV hospital admissions
An Australian-first study demonstrating the effectiveness of a new immunization against respiratory syncytial virus (RSV) for ...
Scientists demonstrate pre-clinical proof of concept for next-gen DNA delivery technology
Scientists in The Wistar Institute lab of David B. Weiner, Ph.D., have described a next-generation vaccination technology ...
Rheumatology Advisor3d
COVID-19 mRNA-1273 Vaccine Highly Protective in Pediatric Patients After 2 Doses
In pediatric patients aged 6 months to 5 years, the VE of mRNA-1273 against symptomatic infection was modest after a single dose and strong after a second dose.